1. United States
2. Ill.
3. Letter

The Patients Before Monopolies Act aims to address the conflicts of interest that arise when corporations own both pharmacy benefit managers (PBMs) and pharmacies. This bipartisan legislation would prohibit such collective ownership, requiring companies to divest from either their PBM or pharmacy operations within three years. The rationale behind this act is to curb the unfair business practices of PBMs that have driven up drug costs, disadvantaged independent pharmacies, and reduced patient access to quality care. PBMs have gained significant control over the pharmaceutical supply chain, leveraging their market power to extract excessive fees and rebates from drug manufacturers. These costs are ultimately passed on to patients through higher out-of-pocket expenses and premiums. The vertical integration of PBMs and pharmacies has exacerbated these issues, creating inherent conflicts of interest that prioritize profits over patient wellbeing. By separating PBMs from pharmacies, the Patients Before Monopolies Act aims to restore competition and transparency in the pharmaceutical industry. Independent pharmacies, which have been disproportionately impacted by the consolidated market power of PBMs, would have a more level playing field. This increased competition could drive down costs and improve access to affordable medications for patients. Furthermore, the act grants enforcement authority to entities such as the Federal Trade Commission (FTC) and state attorneys general, ensuring that violators are held accountable and any ill-gotten gains are redistributed to affected communities. This comprehensive approach addresses the root causes of escalating healthcare costs and aims to prioritize patients over corporate profits.